Nephro-obesity medicine is not currently an accredited board subspecialty, and this page does not claim otherwise. The claim is more modest and practical: the care of patients at the intersection of obesity and kidney disease now requires a coherent skill set not consistently trained to depth in nephrology, endocrinology, or obesity medicine alone. For patients with kidney disease, that skill set should be anchored in nephrology — because the defining endpoints are renal — and built in collaboration with the other fields, not in isolation.
Premise 1 · Epidemiology — two intersecting epidemics
Obesity is an independent, graded risk factor for incident CKD and one of its fastest-growing drivers; it accelerates progression, drives obesity-related glomerulopathy, and complicates dialysis access and transplant candidacy. The link is increasingly supported as causal by Mendelian-randomization and large cohort data, and the population carrying both is large and growing.
Crucially, obesity does not sit beside nephrology; it pervades every one of its subdomains — glomerular disease, haemodialysis, peritoneal dialysis, transplantation, stones, electrolyte and acid–base disorders, AKI and CKD. A driver that touches every part of a specialty, and changes its endpoints, is the kind of thing specialties organise expertise around.
Premise 2 · Mechanism — a distinct pathophysiology
Obesity injures the kidney through specific, increasingly characterised mechanisms; ORG is a nameable lesion with its own histology, distinguishable from diabetic nephropathy and primary FSGS. When a disease has its own mechanism and pathology, obesity is both a disease and a risk modifier, but a condition with its own mechanism and pathology deserves to be engaged in its own right, not treated only as background to other diagnoses.
A field earns a name when it has a mechanism of its own, a diagnostic problem of its own, and a therapeutics of its own. Nephro-obesity now has all three.
Premise 3 · Therapeutics — an inflection between two specialties
The pharmacology of incretins, SGLT2 inhibitors, and non-steroidal MRAs created a multi-pillar cardio-reno-metabolic strategy that must be sequenced and monitored in a failing nephron. The drug pharmacology is owned by endocrinology and obesity medicine; the failing nephron is owned by nephrology. Using these drugs safely in the patient whose kidneys are failing belongs fully to neither — it requires both.
Premise 4 · The training gap
Neither fellowship trains the overlap well: renal-safety surveillance during rapid pharmacological weight loss, dose adjustment in reduced GFR, the protein dilemma, and the perioperative management of the CKD patient going to surgery or a transplant list. These are common, not exotic.
Premise 5 · Why nephrology, specifically
The endpoints that define the field are renal — albuminuria, GFR trajectory, kidney failure, the biopsy, dialysis and transplant. The safety questions are renal. The pathology is renal. Obesity medicine (e.g. ABOM) is an essential complementary competency the nephrologist adds, not the organizing framework.
There is a clean precedent. Nephrology already subspecialises along exactly this kind of intersection: onco-nephrology, cardio-nephrology, interventional nephrology, glomerular disease. Cardio-nephrology is the closest analogy — it emerged when a neighbouring organ system’s therapeutics began to change renal endpoints, and nephrology organised a focused expertise around the overlap rather than leaving it to cardiology alone. Nephro-obesity is the same move one node over, and the CKM framework validates it institutionally.
Premise 6 · Institutional convergence
The major societies are already converging: the AHA CKM framework (2023 advisory; AHA/ACC/ADA/ASN 2026 guideline), the KDIGO Obesity–CKD Controversies Conference (Prague 2024), and the ASN Kidney Health Guidance on obesity (2024). The architecture is being built by the field’s own governing bodies; what is missing is the trained clinician at its centre.
The strongest objection, met directly
The obvious counter is that endocrinology and obesity medicine have the more legitimate claim, because they own the therapeutics. That is real and conceded: incretin pharmacology is theirs, and the discipline cannot function without it. But the question is not who owns the drug — it is who owns the endpoint. Where the defining endpoints and decisive safety questions are renal, the organizing home is nephrology, with obesity-medicine expertise built in as a required, formal competency.
The honest limits of the claim
Nephro-obesity medicine is at present an emerging clinical focus, not an accredited board subspecialty; this page argues for recognition, it does not assert it. Parts of the evidence base are still maturing — several renal endpoints for dual and triple agonists have not yet been reported, and some agents remain investigational.
The Nephrobesity framework set out here — its domains, evidence base, and this case for the discipline — is developed and maintained by Amir Naderi, MD.
Evidence anchors
- Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the AHA. Circulation. 2023.
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of CKM Syndrome.
- KDIGO Controversies Conference: obesity and CKD — pathophysiology, prognosis, management. Prague 2024; Kidney International 2025.
- ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases. J Am Soc Nephrol. 2024;35(11):1574–1588.
- Perkovic V, et al. Semaglutide and CKD in Type 2 Diabetes (FLOW). N Engl J Med. 2024;391:109–121.
- Finerenone in diabetic kidney disease: FIDELIO-DKD and FIGARO-DKD (FIDELITY). Eur Heart J. 2022.